These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28077300)

  • 1. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
    Chuang HC; Huang PH; Kulp SK; Chen CS
    Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.
    Chu PC; Kulp SK; Bekaii-Saab T; Chen CS
    Small GTPases; 2018 Nov; 9(6):452-456. PubMed ID: 27936345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells.
    Chu PC; Yang MC; Kulp SK; Salunke SB; Himmel LE; Fang CS; Jadhav AM; Shan YS; Lee CT; Lai MD; Shirley LA; Bekaii-Saab T; Chen CS
    Oncogene; 2016 Jul; 35(30):3897-908. PubMed ID: 26616862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of RAS: Recent success with direct inhibitors.
    O'Bryan JP
    Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.
    Tan L; Cho KJ; Neupane P; Capon RJ; Hancock JF
    J Biol Chem; 2018 Aug; 293(35):13696-13706. PubMed ID: 29970615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
    Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
    Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic modulation of k-ras signaling in colorectal cancer.
    Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
    Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Ras for cancer treatment: the search continues.
    Baines AT; Xu D; Der CJ
    Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation in pancreatic cancer.
    Luo J
    Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.